AllI · Sterile fill-finish capacityII · Stoppers, syringes & drug-contact componentsIII · Pharmaceutical glass & vialsIV · Bioprocessing consumables & resinsV · API & small-molecule reshoringVI · CDMO capacity & the China exodusVII · Peptide & oligonucleotide manufacturingVIII · Sterile injectables & shortage economicsIX · Analytical instruments & QC releaseX · Private giants & exposure vehicles
| Ticker | Name | Tier ↓ | Quote | Mkt cap | 6M | Chokepoints |
|---|---|---|---|---|---|---|
| A | Agilent Technologies, Inc. | core | $143.12-1.1% | $37.0B | +28.3% | peptides-oligos · instruments-qc |
| BCHMY | Bachem Holding AG (ADR) | core | $9.45-3.4% | $6.7B | +22.6% | peptides-oligos |
| LZAGY | Lonza Group AG (unsponsored ADR) | core | $65.61-1.2% | $41.9B | +8.1% | fill-finish · api-reshoring · cdmo-capacity · peptides-oligos · private-giants |
| CORDENPHARMA | CordenPharma (Astorg) | watch | private | — | via — | peptides-oligos |
| MRVI | Maravai LifeSciences Holdings, Inc. | speculative | $6.73-3.2% | $1.4B | +118.5% | peptides-oligos |
Quote shows the latest price and daily change; the 6M column is the total return over that window. Quotes delayed up to 15 minutes; tiers are editorial conviction, not ratings. Click a column header to sort.